Study Type:
Interventional[Clinical Trial]

Study Design:

Interventional Model: Sequential Assignment
• Intervention Model Description: Lead-in open-label androgen-receptor blocker (ARB) followed by double-blind Radium-223 or placebo.
• Estimated Enrollment: 499 participants
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment

Official Title:
ESCALATE, A Phase III Randomized Study Comparing Enzalutamide or Darolutamide With Radium-223 vs Enzalutamide or Darolutamide With Placebo and the Effect Upon Symptomatic Skeletal Event-Free Survival for mCRPC Patients